
2. Infographic



Summary of results for people diagnosed with Non-Hodgkin Lymphoma (NHL) in England (2020-2021) and Wales (2022).



Diagnosis and staging

Diagnoses per year

14,099 diagnosed in 2020 14,973 diagnosed in 2021

Wales

619 diagnosed in 2022



Mean age at diagnosis for both **England & Wales**

Grade of lymphoma

England 2020-2021

high-grade 51%, low-grade 47%, not classified 1%

Wales 2022

high-grade 49%, low-grade 51%, not classified 0.2%

Clinical Nurse Specialist (CNS) seen, where recorded

82% of people diagnosed with NHL seen by a CNS in England (2020 & 2021) and 96% in Wales.

CNS information was recorded in only 37% of people diagnosed with NHL in England and 69% in Wales.

66%

MDT discussion within 4 weeks of diagnosis, where recorded

England 2020 - 69%,

(high-grade 74.5%, low-grade 61.8%)

England 2021 - 63.5%,

(high-grade 68.6%, low-grade 57.3%)

No data on MDT discussion was provided for Wales



Treatment

Chemotherapy treatment

Percentage of people diagnosed with high grade lymphoma, who received chemotherapy within 62 days of referral.

England 2020





Radiotherapy treatment

Percentage of people diagnosed with high-grade lymphoma, who received radiotherapy within 8 weeks of end of first line chemotherapy.

England 2020



43%



44%

End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

Survival

One-year survival outcomes

